Author
PATTERSON, BLOSSOM - NATIONAL CANCER INST | |
WASTNEY, MERYL - MET MOD SVC, NEW ZEALAND | |
Combs, Gerald | |
BRINDAK, MARY - CORNELL UNIV, ITHACA, NY | |
Patterson, Kristine | |
VEILLON, CLAUDE - USDA, BELTSVILLE, RETIRED | |
TAYLOR, PHILIP - NATIONAL CANCER INST | |
Levander, Orville |
Submitted to: Journal of Federation of American Societies for Experimental Biology
Publication Type: Abstract Only Publication Acceptance Date: 11/1/2005 Publication Date: 3/7/2006 Citation: Patterson, B., Wasteny, M., Combs, G.F., Brindak, M., Patterson, K.K., Veillon, C., Taylor, P., Levander, O.A. 2006. Selenium metabolism in humans: Response of kinetic pools in plasma to 2 yr supplementation. The FASEB Journal Book of Abstracts, Volume 20, No. 5, p. A1069:673.11. Interpretive Summary: Technical Abstract: Selenium (Se) is a particularly promising cancer chemopreventive agent. We have been investigating the effects of oral Se supplementation on the metabolism of two forms of Se, selenomethionine (SeMet) and selenite (Sel), by comparing kinetics for 4-mo before (PK1) and after (PK2) 2 yrs of supplementation with 200 ug of Se as SeMet. For each pharmacokinetic study, thirty free-living subjects (15 M, 15 F) received 2 oral doses of 2 stable isotope tracers, 150 ug of 74Se as SeMet and 150 ug of 76Se as sodium selenite (Sel). A compartmental model requiring ten kinetically distinct compartments in plasma and recirculation of tracer through liver and tissues was developed using data from PK1. The model was then applied to data from PK2. By using the relative absorption of Sel to Se Met and excretion rates of total Se in urine and feces, we were able to combine information on the kinetics of each form and predict the size of each plasma pool in each study. Based on data from 7 subjects, Se-supplementation increased total plasma Se from 132ng/ml to 252 ng/ml with notable increases in five of the plasma pools. Insights into Se metabolism from this investigation will be crucial to interpreting Se-intervention results, such as those of the 35,000+ male subject SELECT prostate cancer prevention trial. |